PT-141 bremelanotide: Receptors and structural evidence

What is PT-141 bremelanotide?

The development review describes bremelanotide, cataloged as PT-141 (Bremelanotide), as a synthetic peptide analog of alpha melanocyte-stimulating hormone (α-MSH) and a melanocortin receptor agonist. ^[1]

A peptide is a molecule built from linked amino acid units. An analog is a modified relative of a reference molecule. An agonist is a molecule that activates a receptor. These terms distinguish molecular identity, chemical relationship, and receptor activity; they do not provide a complete chemical specification.

The development review identifies α-MSH as a neuropeptide hormone and describes bremelanotide's relationship to it, but its abstract does not provide an amino acid sequence or structural drawing. ^[1] Hedlund's early research review describes PT-141 more specifically as a synthetically modified analog of PT-14, also without reporting a sequence in the abstract. ^[2]

The review literature therefore supports an analog relationship and a receptor-agonist classification more directly than it supports a detailed structural reconstruction from the abstracts. ^{[1, 2]}

Is PT-141 selective for MC3R or MC4R?

The development review reports high affinity for the melanocortin type 4 receptor (MC4R), but its abstract does not establish a quantitative selectivity comparison with the melanocortin type 3 receptor (MC3R). ^[1]

Binding affinity describes how strongly a molecule interacts with a receptor in a binding assay. Functional potency describes the concentration associated with a defined response in a functional assay. Functional efficacy describes the response achieved in that assay. These are different measurements, so a qualitative affinity statement should not be read as a numerical potency or efficacy result.

The distinction is important: the development review supplies a qualitative MC4R affinity statement, not an original comparative binding experiment in its abstract. ^[1] The mechanism review likewise does not provide a numerical receptor-subtype comparison in its abstract. ^[3]

What does bremelanotide's mechanism of action mean?

The development and mechanism reviews identify melanocortin receptor agonism but do not map receptor-specific intracellular signaling in their abstracts. ^{[1, 3]}

Signaling means the molecular events associated with receptor activation. A downstream event is a later event in that sequence. A proposed pathway and a directly measured signaling event are different levels of evidence.

The mechanism review discusses proposed action and human research, but its abstract does not identify a cell-based experiment that connects a particular melanocortin receptor to a specified intracellular signal. ^[3] The development-review abstract does not present a receptor-to-intracellular-signal experiment. ^[1]

A registered phase 4 study (see registry record) lists randomized allocation, quadruple masking, bremelanotide and placebo, and completed status. ^[5] Its sponsor class is listed as OTHER. ^[5] That registry record describes a study design; it does not report a receptor-subtype binding panel or a resolved intracellular signaling sequence. ^[5]

Keep proposed mechanisms, measured receptor pharmacology, and registry design facts separate when reading the research record.

What is known about the amino acid sequence and structure?

A complete amino acid sequence and cyclization map are not reported in the development review or Hedlund's review abstract. ^{[1, 2]}

An amino acid sequence identifies the linked residues. Cyclization means formation of a closed molecular ring. A lactam linkage is an amide bond within a ring. Stereochemistry describes the spatial arrangement of atoms, while terminal groups identify the chemical groups at the ends of a chain.

The development review's description of a synthetic α-MSH analog does not specify residue identities, stereochemistry, terminal groups, or a lactam linkage in its abstract. ^[1] Hedlund's description of a modified PT-14 analog likewise does not supply those structural details. ^[2]

The PT-141–melanotan II structural comparison remains unresolved at the level of these review abstracts: neither reports an explicit comparison of the molecules' sequences or terminal groups. ^{[1, 2]} The PT-14 designation in Hedlund's abstract should therefore not be interpreted as an explicit structural comparison with melanotan II. ^[2]

A structural drawing would require a direct chemical reference rather than an expansion of the word “analog.” For the same reason, an annotated sequence should distinguish documented features from features that remain unverified.

What does the research history establish?

The dated literature documents an early analog description, later receptor-focused reviews, and human study designs, but the review abstracts do not establish an original chemical-characterization milestone. ^{[1, 2, 3, 4]}

• 2004 — Early research description: Hedlund's review identifies PT-141 as a synthetically modified analog of PT-14. ^[2]
• 2015 — Study registration: NCT02333071 is a registered phase 3 study (see registry record) with randomized allocation, a placebo comparator, and an industry sponsor; the record lists completed status. ^[6]
• 2019 — Development review: Dhillon and Keam describe bremelanotide as a synthetic α-MSH analog and report high affinity for MC4R. ^[1]
• 2019 — Mechanistic study registration: NCT04179734 is a registered phase 4 study (see registry record) with randomized allocation and quadruple masking; the record lists completed status. ^[5]
• 2021 — Bridging study registration: NCT04943068 is a registered phase 3 study (see registry record) with a multicenter, randomized, placebo-controlled, parallel-group design and an industry sponsor; the record lists completed status. ^[7]
• 2022 — Human research report: Simon and colleagues describe randomized, double-blind, placebo-controlled phase 3 studies with an optional 52-week open-label extension. ^[4]
• 2023 — Mechanism review: Cipriani and colleagues summarize proposed mechanisms and human research; their abstract does not report a receptor-specific intracellular signaling experiment. ^[3]

A publication year identifies a report, while a registration year identifies a registry entry. Neither should be substituted for the date of chemical discovery without a direct historical reference. Likewise, a completed registry status describes study progress, not the establishment of a molecular mechanism.

How should identity and lot documentation be read?

Chemical identity, lot documentation, and receptor evidence answer different questions and should be read separately.

An identity assessment asks whether material matches a specified chemical identity. An analytical record concerns a particular sample. A receptor study asks how defined material behaves in an experimental system. None of these document types should silently stand in for another.

A certificate of analysis (COA) is a document reporting analytical results for identified material. For lot-specific records, consult the COA library. For help interpreting document fields, see How to read a Certificate of Analysis.

For literature interpretation, keep the evidentiary boundary equally explicit: the development review supports a synthetic α-MSH analog classification and qualitative MC4R affinity, while its abstract leaves the complete sequence and comparative receptor measurements unspecified. ^[1] The human research report adds study-design information, not a chemical specification or a receptor-selectivity experiment in its abstract. ^[4]

A clear research record keeps those distinctions visible rather than using a familiar compound name to fill missing structural or experimental details.